NCT01668173: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET |
|
|
| Terminated | 2 | 7 | US | AUY922 | Memorial Sloan Kettering Cancer Center, Novartis | Myeloproliferative Neoplasms | 05/15 | 05/15 | | |
